Clinical Trial Search

Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029

Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 97; 138; 131; 269 Participants

Primary: Global Infarct Size — 5.453; 8.598; 9.004; 7.819 Percentage of global infarct size

Primary: The Percentage of Participants With Occurrence of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Urgent Revascularization (UR), or Glycoprotein (GP)…

Primary: Ischemia Area at Risk as Determined by Paired Single-photon Computed Tomography Studies With Technetium Tc99m Sestamibi.

Primary: Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion — 15.1; 17.9; 17.2 Percentage of Left…

Primary: Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB) — 6582.0; 6738.3; 5252.2; 5471.9 ng*hr/mL

Primary: The Sensitivity and Specificity of ECG for Acute Coronary Occlusion. — 767; 282; 16 Participants

Primary: Arrhythmias of Interest, 48 Hours (Overall) — 0; 0; 0; 0 participants

Primary: Number of Patients With ST-segment Elevation Resolution Equal or More Than 50% — 47; 51 participants — p=0.56

Primary: Index of Microcirculatory Resistance — 21.94; 23.22; 32.95 IMR

Primary: Number of Participants With Spontaneous Reperfusion — 2 participants

Primary: Infarct Size on Baseline Cardiac Magnetic Resonance Imaging (cMRI) — 20.1; 21.0 ml — p=0.90

Primary: Peri-Procedural Myocardial Injury — 23; 29 Participants

Primary: Composite of: Cardiovascular Death*, Re-myocardial Infarct, Re-hospitalization for Heart Failure (HF) and Congestive Heart Failure (CHF), Resuscitation or ICD…

Primary: Number of Patients With Major Adverse Cardiac Event — 42; 0; 437; 123 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 28; 30; 31; 14 Participants

Primary: Change From Baseline to Day 253 in Non-calcified Plaque Volume in the Most Diseased Coronary Segment (NCPVMD), as Measured by Computed Tomography Angiography (CTA)…

Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L

Primary: Changes of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels — -84.9; -82.2 pg/mL

Primary: Number of Participants With Complete Sum ST Resolution (STR) 60 Minutes (Min) After Percutaneous Coronary Intervention (PCI) (Per Protocol Population) — 71; 65…

Primary: Improvement in Left Ventricular Ejection Fraction — 53.1; 54.8 % of LVEF

Primary: Clinical Performance - Area Under the Curve — 0.9326; 0.9197; 0.9412; 0.9431 Probability

Primary: Number of Participants With Fatal/Life-threatening Bleedings — 4 Participants

Primary: Emergency Room Visits — 40; 33 Emergency Room Visits

Primary: High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Multiple Imputation Procedure) — 106.84; 107.65; 184.30 mg*day/L

Primary: Number of Death — 417; 137; 552 Participants

Primary: Composite of Incidence of Death, Reinfarction, Unstable Angina Pectoris, Stroke, Unplanned Rehospitalization, Repeat Target Vessel Revascularization and Stent Thrombosis…

Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…

Primary: Length of Hospital Stay — 23.2; 30.8 hours